Successes and failures in elaboration of novel approaches to drug treatment of chronic heart failure (review of results of randomized trials conducted in the ninetieths). Part I

被引：0

作者：

Preobrazhensky, DV ^{[1
]}

Sidorenko, BA ^{[1
]}

机构：

[1] Russian President Med Ctr, Moscow, Russia

来源：

KARDIOLOGIYA | 2000年 / 40卷 / 03期

关键词：

heart failure; chronic; digoxin; nonglycoside inotropic drugs; diuretics; spironolactone;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In a series of articles the authors review results of randomized controlled trials of drug therapy of patients with chronic heart failure. The present paper contains discussion of evidence-based data on the use of digoxin, nonglycoside inotropic agents and aldosterone receptor antagonist spironolactone.

引用

页码：52 / 60

页数：9

共 24 条

[1] Patients with mild heart failure worsen during withdrawal from digoxin therapy
Adams, KF
Gheorghiade, M
Uretsky, BF
Young, JB
Ahmed, S
Tomasko, L
Packer, M
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (01) : 42 - 48
[2] EFFECTS OF VESNARINONE ON MORBIDITY AND MORTALITY IN PATIENTS WITH HEART-FAILURE
FELDMAN, AM
BRISTOW, MR
PARMLEY, WW
CARSON, PE
PEPINE, CJ
GILBERT, EM
STROBECK, JE
HENDRIX, GH
POWERS, ER
BAIN, RP
WHITE, BG
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) : 149 - 155
[3] GEHROGHIADE M, 1992, AM J CARDIOL, V69, pG48
[4] Pharmacotherapy for systolic dysfunction: A review of randomized clinical trials
Gheorghiade, M
Benatar, D
Konstam, MA
Stoukides, CA
Bonow, RO
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (8B) : H14 - H27
[5] Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure
Hampton, JR
vanVeldhuisen, DJ
Kleber, FX
Cowley, AJ
Ardia, A
Block, P
Cortina, A
Cserhalmi, L
Follath, F
Jensen, G
Kayanakis, J
Lie, KI
Mancia, G
Skene, AM
[J]. LANCET, 1997, 349 (9057) : 971 - 977
[6] Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial
Heyndrickx, G
Renard, M
Beil, S
Doering, W
Kauder, E
Klepzig, H
Schacherer, C
Haass, M
Kruger, C
Limbourg, P
Liomin, E
Maisch, B
Schartl, M
Simon, H
Bernink, PJLM
Fels, PW
Dohmen, HJM
Dunselman, PHJM
Baselier, MRP
Holwerda, NJ
Laarman, GJ
Leenders, CM
vanLeeuwen, K
Michels, HR
vanderEnt, M
Remme, WJ
Withagen, AJAM
Gundersen, T
Otterstad, JE
Froland, G
Pedersen, TR
Ferreira, JRG
deSa, EP
SeabraGomes, R
Gil, V
Abdon, NJ
Jonsson, J
Lubsen, J
[J]. HEART, 1996, 76 (03) : 223 - 231
[7] CAN FURTHER BENEFIT BE ACHIEVED BY ADDING FLOSEQUINAN TO PATIENTS WITH CONGESTIVE-HEART-FAILURE WHO REMAIN SYMPTOMATIC ON DIURETIC, DIGOXIN, AND AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR - RESULTS OF THE FLOSEQUINAN-ACE INHIBITOR TRIAL (FACET)
MASSIE, BM
BERK, MR
BROZENA, SC
ELKAYAM, U
PLEHN, JF
KUKIN, ML
PACKER, M
MURPHY, BE
NEUBERG, GW
STEINGART, RM
LEVINE, TB
DEHAAN, H
[J]. CIRCULATION, 1993, 88 (02) : 492 - 501
[8] MCMURRAY J, 1997, CONTROVERSIES MANAGE, P41
[9] Treating, chronic heart failure: Time to take stock
Niebauer, J
Coats, AJS
[J]. LANCET, 1997, 349 (9057) : 966 - 967
[10] PACKE RM, 1999, AM J CARDIOL, V83, pA1

← 1 2 3 →